| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $30.1M | +1.2% | -43.4% |
| SG&A Expense | $10.3M | -0.5% | -26.8% |
| Operating Income | -$43.5M | +54.2% | +29.5% |
| Net Income | -$42.2M | +55.1% | +29.7% |
| EPS (Basic) | -$0.16 | +59.0% | +36.0% |
| EPS (Diluted) | -$0.16 | +59.0% | +36.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $103.4M | +45.0% | -18.6% |
| Short-term Investments | $49.7M | +3442.2% | -31.0% |
| Current Assets | $161.8M | +96.1% | -23.0% |
| Total Assets | $435.4M | +20.4% | -22.2% |
| Current Liabilities | $35.5M | +6.2% | -24.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$111.2M | — | — |
| Capital Expenditures | $65K | — | — |
| Investing Cash Flow | -$23.7M | — | — |
| Financing Cash Flow | $111.1M | — | — |
| Free Cash Flow | -$111.3M | — | — |
| $240.1M |
| +0.4% |
| -10.0% |
| Stockholders' Equity | $195.3M | +59.4% | -33.2% |